{"title":"The Inhibitory Effects of Cordycepin on Phosphoproteins including PI3K, Akt, and p38","authors":"Hyuk-Woo Kwon, Dong-Ha Lee","doi":"10.15324/KJCLS.2017.49.2.99","DOIUrl":null,"url":null,"abstract":"A species of Cordyceps, an ingredient in Chinese traditional medicine well-known for its major component, cordycepin (3'-deoxyadenosine), has been known to have antiplatelet effects; however, its effects on regulation of phosphoprotein have not been fully elucidated. In this study, we investigated how cordycepin regulates the phosphoprotein, including phosphatidylinositol 3-kinase (PI3K)/Akt and p38, to inhibit platelet aggregation, which are concerned with fibrinogen binding to glycoprotein IIb/IIIa (IIb/3) and granule secretion in platelets. Our finding suggests that cordycepin inhibits collagen-induced platelet aggregation with 261.1 M of IC50 and also inhibits fibrinogen binding to IIb/3 by a suppression of PI3K/Akt phosphorylation in a dose dependent manner. In addition, cordycepin further showed to inhibit collagen-induced p38 phosphorylation, reducing granule secretion (i.e. ATPand serotonin-release) and thromboxane A2 (TXA2) production without regulating cyclooxygenase-1 (COX-1) and thromboxane A synthase (TXAS) activities, as well as phospholipase C-2 (PLC-2) phosphorylation. In conclusion, these results demonstrate that cordycepin-mediated antiplatelet effects were due to the inhibition of fibrinogen binding to IIb/3 via the suppression of PI3K/Akt phosphorylation and inhibition of granule secretion & TXA2 production by suppressing p38 phosphorylation. These results strongly indicate that cordycepin might have therapeutic or preventive potential for platelet aggregation-mediated disorders, regulating the phosphoprotein, including PI3K/Akt and p38.","PeriodicalId":10080,"journal":{"name":"临床检验杂志","volume":"387 1","pages":"99-107"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"临床检验杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15324/KJCLS.2017.49.2.99","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
A species of Cordyceps, an ingredient in Chinese traditional medicine well-known for its major component, cordycepin (3'-deoxyadenosine), has been known to have antiplatelet effects; however, its effects on regulation of phosphoprotein have not been fully elucidated. In this study, we investigated how cordycepin regulates the phosphoprotein, including phosphatidylinositol 3-kinase (PI3K)/Akt and p38, to inhibit platelet aggregation, which are concerned with fibrinogen binding to glycoprotein IIb/IIIa (IIb/3) and granule secretion in platelets. Our finding suggests that cordycepin inhibits collagen-induced platelet aggregation with 261.1 M of IC50 and also inhibits fibrinogen binding to IIb/3 by a suppression of PI3K/Akt phosphorylation in a dose dependent manner. In addition, cordycepin further showed to inhibit collagen-induced p38 phosphorylation, reducing granule secretion (i.e. ATPand serotonin-release) and thromboxane A2 (TXA2) production without regulating cyclooxygenase-1 (COX-1) and thromboxane A synthase (TXAS) activities, as well as phospholipase C-2 (PLC-2) phosphorylation. In conclusion, these results demonstrate that cordycepin-mediated antiplatelet effects were due to the inhibition of fibrinogen binding to IIb/3 via the suppression of PI3K/Akt phosphorylation and inhibition of granule secretion & TXA2 production by suppressing p38 phosphorylation. These results strongly indicate that cordycepin might have therapeutic or preventive potential for platelet aggregation-mediated disorders, regulating the phosphoprotein, including PI3K/Akt and p38.